Despite great progress on case–control polygenic prediction, an unmet need remains for a method that genetically distinguishes clinically related disorders (e.g., schizophrenia (SCZ) versus bipolar disorder (BIP) versus major depressive disorder (MDD) versus controls). We introduce differential diagnosis–polygenic risk...
W. Peyrot, G. Panagiotaropoulou, L. O. Olde Loohuis et al.· Nature Genetics· 0 citations
Introduction Limitations of current classifications of schizophrenia, schizoaffective disorder, and bipolar disorder are evident from their overlapping symptoms, aetiologies, treatments, and outcomes, and present a barrier to novel treatment discovery. Alternative conceptualisations are needed to address nosological va...
Charlotte A. Dennison, S. Legge, A. Cardno et al.· medRxiv· 0 citations
Findings provide proof-of-concept for the utility of pPGSs in psychiatric research, suggesting both genetic contributions to trauma exposure and GxE effects on psychosis risk, as well as supporting pathway-specific contributions beyond general polygenic risk.
G. Trotta, I. Austin-Zimmerman, E. Spinazzola et al.· Translational Psychiatry· 0 citations
Prolonged CAL is linked to higher risk of FEP, preferentially affective psychosis in females, poorer functioning, and developmental potentiation of polygenic liability.
Á. Andreu-Bernabeu, J. González-Peñas, M. Bernardo et al.· Schizophrenia bulletin· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.